Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies
- 25 Downloads
Purpose of Review
This review seeks to detail the clinical and pathologic features specific to BRAFV600E colorectal cancer. Application of novel preclinical findings translated into the clinic for the development of new therapeutic options for patients with BRAFV600E metastatic colorectal cancer will be detailed.
While BRAF inhibitors as monotherapy do not have the same clinical activity for colorectal cancer relative to other solid tumors harboring an oncogenic BRAFV600E mutation, combination approaches targeting BRAF + MEK + EGFR hold promise for patients with BRAFV600E colorectal cancer.
Simultaneous targeting of multiple drivers along the MAPK pathway improves clinical outcomes for patients with BRAFV600E colorectal cancer. Targeted therapies and immunotherapy hold great promise in the years to come for patients with this subtype of colorectal cancer.
KeywordsColorectal cancer BRAF Immunotherapy Targeted therapy Clinical trial Biomarker
Compliance With Ethical Standards
Conflict of Interest
The author declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 9.Gonsalves WI, Mahoney MR, Sargent DJ, et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014;106(7).Google Scholar
- 13.Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57(5):808–11.Google Scholar
- 19.O’Brien MJ, Yang S, Mack C, et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol. 2006;30(12):1491–501.CrossRefGoogle Scholar
- 29.Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and Mitomycin in advanced colorectal Cancer. J Clin Oncol. 2011;29(19):2675–82.CrossRefGoogle Scholar
- 36.• Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112(12):1888–94 BRAF V600E mutation is not predictive for benefit to anti-EGFR therapies in patients with metastatic colorectal cancer. CrossRefGoogle Scholar
- 40.Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013;14(8):749–59.CrossRefGoogle Scholar
- 43.Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–15.CrossRefGoogle Scholar
- 60.• Kopetz S, Desai J, Chan E, et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol. 2015;33(34):4032–8 Unlike other advanced malignancies, BRAF inhibitor as a monotherapy is not an effective treatment approach for patients with BRAF V600E metastatic colorectal cancer. CrossRefGoogle Scholar
- 62.JD CAG-R, Robert C, Hidalgo M, von Moos R, Arance A, Elez E, et al. Encorafenib (LGX818), an oral BRAF inhibitor, in patients (pts) with BRAF V600E metastatic colorectal cancer (mCRC): results of dose expansion. Ann Oncol. 2014;25(suppl 4):iv167-iv209.Google Scholar
- 64.•• Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–3 In preclinical models of BRAF V600E colorectal cancer, blockade of BRAF V600E generates reflexive activation of EGFR and downstream MAPK signaling. CrossRefGoogle Scholar
- 68.•• Kopetz S, McDonough SL, Morris VK, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol. 2017;35(4_suppl):520–520 The addition of cetuximab to the BRAF inhibitor vemurafenib improves survival outcomes in patients with BRAF V600E metastatic colorectal cancer. CrossRefGoogle Scholar
- 69.Network. NCC. NCCN Guidelines Colon Cancer, version 4.2018. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 23 Oct 2018.
- 73.• Ahronian LG, Sennott EM, Van Allen EM, et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 2015;5(4):358–67 Resistance to targeted therapies against BRAF and EGFR in patients with BRAF V600E metastatic colorectal cancer may be driven by acquired activating mutations in genes relevant to propagating MAPK signaling. CrossRefGoogle Scholar
- 75.•• Van Cutsem E, Cuyle P, Huijberts S, et al. O-027BEACON CRC study safety lead-in: assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. Ann Oncol. 2018;29(suppl_5):mdy149.026-mdy149.026 Targeted therapies against BRAF, MEK, and EGFR are safe and active for patients with BRAF V600E metastatic colorectal cancer. Google Scholar
- 76.Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91.CrossRefGoogle Scholar
- 77.•• Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–9 Patients with BRAF V600E metastatic colorectal cancer and microsatellite instability demonstrate sustained clinical response to immune checkpoint blockade therapy. CrossRefGoogle Scholar